STOCK TITAN

Rafael Holdings Inc - RFL STOCK NEWS

Welcome to our dedicated news page for Rafael Holdings (Ticker: RFL), a resource for investors and traders seeking the latest updates and insights on Rafael Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rafael Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rafael Holdings's position in the market.

Rhea-AI Summary
Rafael Holdings, Inc. (NYSE: RFL) reports financial results for Q2 fiscal 2024, showing a net income of $5.9 million and increased ownership in Day Three Labs to 79%. The company aims to enhance shareholder value through strategic investments and portfolio advancement, welcoming Dr. John Goldberg as Chief Medical Officer. Notable progress in Cyclo Therapeutics' Phase 3 trial for Niemann-Pick Disease Type C and Day Three Labs' innovative cannabis products development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary
Rafael Holdings, Inc. (NYSE: RFL) reported its Q1 fiscal 2024 results, emphasizing a focus on advancing the portfolio and identifying strategic investments. The company holds $72.1 million in cash, cash equivalents, and marketable securities. It reported a net loss of $3.8 million, down from $5.2 million a year ago. Research and development expenses decreased to $0.5 million from $2.1 million, while general and administrative expenses decreased to $2.0 million from $3.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) reported strong enrollment in its pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”). The company is also on track to close a merger with Applied Molecular Transport, Inc. before the year ends. Additionally, they have taken steps to strengthen their balance sheet and extend their cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
Rhea-AI Summary
Rafael Holdings, Inc. reported its financial results for Q4 and full year fiscal 2023. They curtailed expenses and increased liquidity by selling their real estate. They invested in Cyclo Therapeutics and Day Three Laboratories. They had cash and marketable securities of $79.2 million as of July 31, 2023. Net income from continuing operations for Q4 was $1.3 million, compared to a net loss of $4.6 million in the same period last year. R&D expenses decreased from $1.8 million to $1.3 million. General and administrative expenses decreased from $3.0 million to $1.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
-
Rhea-AI Summary
Cyclo Therapeutics reports strong enrollment progress in pivotal Phase 3 study for Niemann-Pick Disease Type C1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
-
Rhea-AI Summary
Cyclo Therapeutics closes private placement with Rafael Holdings for $5,000,000, to be used for working capital and Trappsol® Cyclo™ development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.4%
Tags
Rhea-AI Summary
Cyclo Therapeutics closes private placement with Rafael Holdings for the purchase of common stock and warrants. The gross proceeds of the private placement were $2.1 million. William Conkling, Rafael's CEO, will join the Board of Directors of Cyclo Therapeutics. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.97%
Tags
none
Rafael Holdings Inc

NYSE:RFL

RFL Rankings

RFL Stock Data

40.81M
15.83M
20.55%
11.86%
0.16%
Real Estate Services
Real Estate
Link
United States
Newark

About RFL

we are a wholly owned subsidiary of rafael holdings focused on pipeline development